Risk factors of immune checkpoint inhibitor-associated acute kidney injury: evidence from clinical studies and FDA pharmacovigilance database

Table 2 Quality assessment of eligible studies with the Newcastle–Ottawa Scale

Study	Selection				Comparability	Outcome			Scores
Study	1	2	3	4	5	6	7	8	Scores
Meraz-Muñoz A 2020 [10]	✔	✔	✔		✔✔	✔	✔	✔	8
Abdelrahim 2021 [3]			✔	✔	✔✔	✔	✔	✔	7
Seethapathy 2019 [5]	✔	✔	✔		✔✔	✔	✔	✔	8
Cortazar 2020 [9]	✔		✔		✔✔	✔	✔	✔	7
Koks 2021 [4]	✔	✔	✔		✔✔	✔	✔	✔	8
Shimamura 2021[13]	✔	✔	✔		✔✔	✔	✔	✔	8
Stein 2020 [11]			✔		✔✔	✔	✔	✔	6
Seethapathy 2020 [12]			✔		✔	✔	✔	✔	5
Gupta 2021 [14]	✔	✔	✔		✔✔	✔	✔	✔	8

ISSN: 1471-2369